Ligand Pharma (LGND) Misses Q1 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $316.18 +0.85%
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Gain on sale of a product line: 0
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.63, $0.21 worse than the analyst estimate of $1.84. Revenue for the quarter came in at $51.72 million versus the consensus estimate of $59.07 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- SMX -- Good Intentions Don't Count; Measured Plastic Does
- DICK'S Sporting Goods, Inc. Signs Caitlin Clark as First-Ever Brand Partner Across DICK'S and Foot Locker
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
